Please login to the form below
squamous cell cancer
This page shows the latest squamous cell cancer news and features for those working in and with pharma, biotech and healthcare.
Sanofi, Regeneron's Libtayo shows marked reduction in risk of death in cervical cancer patients
It included women with either cervical squamous cell carcinoma or adenocarcinoma, who were randomised to receive Libtayo monotherapy or an investigator’s choice of commonly used chemotherapy. ... As a latecomer to the immunotherapy class, Libtayo first
Latest news
-
Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US
As a latecomer to the immunotherapy class, Libtayo first entered the market in 2018 with an approval in advanced cutaneous squamous cell carcinoma, a form of skin cancer. ... advanced non-small cell lung cancer,” said Israel Lowy, senior vice president,
-
Merck strengthens oncology pipeline with $2.75bn VelosBio deal
Merck &Co (MSD) has agreed to acquire VelosBio for $2.75bn, giving MSD access to a number of potential cancer treatments in the process. ... breast cancer (TNBC), hormone receptor-positive and/or HER2-positive breast cancer and non-squamous non-small
-
Immutep slumps on latest efti data in breast cancer
down by a third as investors all-but wrote off the drug in breast cancer. ... lung cancer (NSCLC) and head and neck squamous cell carcinoma of the (HNSCC).
-
J&J’s bispecific lung cancer antibody nabs FDA breakthrough status
JNJ-61186372 (JNJ-6372) is in trials as a treatment for adults with non-small cell lung cancer (NSCLC) EGFR exon 20 insertion mutations, a patient group with no FDA-approved ... other cancer types including a rare head and neck cancer known as sinonasal
-
Immutep spikes on trial of its LAG-3 drug with Keytruda
Impressive mid-stage results in NSCLC and HNSCC. Shares in Australian biotech Immutep rose quickly on data for its cancer immunotherapy drug eftilagimod alpha alongside Merck &Co’s Keytruda in solid ... tumours. Most of those gains dissipated after the
Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US
Merck strengthens oncology pipeline with $2.75bn VelosBio deal
Immutep slumps on latest efti data in breast cancer
J&J’s bispecific lung cancer antibody nabs FDA breakthrough status
More from news
Approximately 0 fully matching, plus 63 partially matching documents found.
Latest Intelligence
-
Immuno-oncology in 2019: the rapid evolution continues
It sealed its dominance last year with a string of successful endpoint-hitting trials, most especially in non- small cell lung cancer (NSCLC). ... Keytruda extends its lead. Keytruda established itself as the new standard for first-line treatment of
-
Chinese biotech’s global ambitions
has just achieved a landmark approval in China for its own ‘home-grown’ cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal
Immuno-oncology in 2019: the rapid evolution continues
Chinese biotech’s global ambitions
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
BIND Therapeutics appoints Andrew Hirsch as permanent CEO
Its lead compound, BIND-014, is currently in phase II clinical trials for KRAS-mutant and squamous histology non-small cell lung cancer.
BIND Therapeutics appoints Andrew Hirsch as permanent CEO
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Therapy Watch expands oncology and IBD portfolios
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
-
Events Executive
-
Depending on Experience
-
Digital account director
-
Competitive
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Distracted boyfriend: the secret of a successful long-distance relationship
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- Vertex gains FDA fast track designation for diabetes stem cell therapy
- Onyx Health Launch Creative Studio After Record Year
- Roche appoints Philip Atkinson to new global role
- AZ’s comeback drug cediranib stumbles in phase 3 trial
- MHRA outlines two-year delivery plan with ‘patient first’ focus
PMHub
Hamell
Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
